close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Gilead Sciences, Inc.

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Prices $2 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Announces Second Quarter 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today